Cancer Care Ontario | Action Cancer Ontario

The objective of the Medical Physics Residency Program is to train medical physicists to perform duties competently, professionally and safely in a...

Regimen

MFOLFOX6+ZOLB

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2025

Guidelines and Advice

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline

Status: Current
ID: GL 1-23-A

Jul 2021

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Dec 1969

Regimen

MIRV

Cancer Type:

Gynecologic,

Ovary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

mirvetuximab soravtansine (Compassionate)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2025

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

asciminib

ABIRPRED

AZCTIVOS

Algorithmes de tests réflexifs de biomarqueurs du SNC

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

MATRIX

Medical Physics Residency Program

MFOLFOX6+ZOLB

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

MIRV

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Pages